(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.
Traws Pharma's earnings in 2026 is -$14,750,000.On average, 4 Wall Street analysts forecast TRAW's earnings for 2026 to be -$21,991,196, with the lowest TRAW earnings forecast at -$27,260,599, and the highest TRAW earnings forecast at -$16,067,284. On average, 4 Wall Street analysts forecast TRAW's earnings for 2027 to be -$19,726,171, with the lowest TRAW earnings forecast at -$29,442,295, and the highest TRAW earnings forecast at -$9,067,675.
In 2028, TRAW is forecast to generate -$8,654,062 in earnings, with the lowest earnings forecast at -$8,314,687 and the highest earnings forecast at -$8,908,593.